Jämför metoder

	Hemolysanalys	Elektrospinning	MTT/MTS-analysen
Ämnesområde	Biomaterial	Biomaterial	Biomaterial
Familj	Process / pipeline	Process / pipeline	Process / pipeline
Ursprungsår	1950	1934	1983
Upphovsperson	Clinical hematology traditions	Anton Formhals	Tatsuro Mosmann
Typ	Hemolytic compatibility assay	Fiber fabrication process	Colorimetric assay
Ursprungskälla	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.	Formhals, A. (1934). Process and apparatus for preparing artificial threads. U.S. Patent 1,975,504.	Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63.
Alias	RBC lysis assay, hemolytic compatibility test, hemolytic potential test	electrospun fiber production, electrostatic fiber spinning	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay
Närliggande	4	3	4
Sammanfattning	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.	Electrospinning is an electrostatic fiber fabrication process that uses a high electric field to draw polymer solutions or melts into nanoscale fibers. Developed by Anton Formhals in the 1930s and refined by researchers including Darrell Reneker in the 1990s, the technique has become foundational to biomaterials engineering, enabling the creation of porous scaffolds for tissue engineering and drug delivery systems.	The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development.